Not Yet a Prescription: A Patient Wants the Drug He Read About Last Month
A man asks for retatrutide by name after reading about its Phase 3 weight-loss results — a drug with no FDA approval, no submitted application, and no legitimate source outside an actively enrolling outcomes trial.
Marcus L., a 49-year-old insurance adjuster, arrived at his appointment with a printed news article about a trial called TRIUMPH-1 folded in his jacket pocket, the specific number — up to 28.3% average weight loss — underlined twice in pen. He's tried semaglutide and, more recently, tirzepatide, with real but partial results each time — a history that matters more than the frustration attached to it, since a man who has already responded partially to both single- and dual-incretin therapy is exactly the profile a third mechanism is hypothesized to reach, and exactly the profile for whom no one yet has the data to promise it will, and had already decided, before the visit started, that the drug in the article was the one he actually wanted next. He asked for it by its investigational name, retatrutide, with the same confidence he might have used asking for a refill, and seemed genuinely surprised when his physician's first response was a question rather than a prescription pad.
The honest answer required correcting a premise the article itself hadn't been careless about, but that Marcus had filled in on his own: retatrutide is not an approved drug. Eli Lilly has reported positive topline results across five Phase 3 trials as of mid-2026, spanning obesity, type 2 diabetes, knee osteoarthritis, and cardiovascular disease populations. Two things about that list bear on Marcus specifically. The cardiovascular arm his article leaned on enrolled patients with established atherosclerotic disease, and his hypertension alone does not put him in it. And no New Drug Application for the obesity indication has been submitted to the FDA yet — Lilly has guided to late 2026 or the first quarter of 2027 — meaning the earliest realistic path to an actual prescription is still well over a year away, regardless of how compelling the trial numbers already look on paper.
In clinic, a name from an article and a real regulatory gap
I understand exactly why he's asking, and I still can't prescribe it to him. Retatrutide isn't FDA-approved for any indication as of today — Lilly has reported positive topline results across five Phase 3 trials, including up to 28.3% mean weight loss at the highest dose in TRIUMPH-1, but a New Drug Application hasn't even been submitted yet, guided to late 2026 or the first quarter of 2027. Anything he could obtain outside a registered clinical trial right now would be unregulated, sourced without the safety infrastructure that trial participants actually have.
I'd add the specific risk of what 'unregulated' means here, since I don't think the abstract warning lands the same way as the concrete one: compounded or gray-market versions of an investigational triple agonist carry all the same identity and purity uncertainties we already worry about with compounded semaglutide and tirzepatide, but without even an approved reference product's own trial data to compare a bad batch against. There's no FDA-approved retatrutide label to know he's deviating from.
What I can offer him honestly is a real path, not just a no: there are open retatrutide trials he may be eligible for. I'd flag one thing honestly first: TRIUMPH-Outcomes, the cardiovascular and kidney trial, requires established atherosclerotic disease or chronic kidney disease alongside a BMI of 27 or higher, and his hypertension alone doesn't meet that — so the arm he's most likely read about is the one he probably can't enter. The obesity-program studies still enrolling are the realistic route, and his BMI of 35 with two documented partial responses puts him squarely in the population they want. Trial participation gets him access to the drug under real clinical monitoring, with adverse events tracked and acted on the way they weren't for patients who've sourced other investigational-stage drugs on their own.
I'd also be honest that trial enrollment isn't guaranteed and involves randomization — he might receive placebo — which is a real limitation compared to simply being handed a prescription, but it's the legitimate path that exists right now, not a consolation prize.
Agreed: refer Marcus for TRIUMPH-Outcomes trial screening as the only legitimate current path to retatrutide, while starting tirzepatide today so he isn't left without active treatment while eligibility is confirmed and, if enrolled, during any placebo-controlled period.
No real disagreement remained between the two physicians; Marcus was told directly, and without hedging, that no legitimate prescription pathway exists yet outside that trial, and that any product obtained another way could not be trusted to be what it claimed to be.